New York, NY -- (ReleaseWire) -- 07/23/2013 -- Growing Stock Report expands its NASDAQ Active Stock Watch List adding BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Mylan, Inc. (NASDAQ:MYL).
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a biotechnology company that designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases closed up in its previous session (+51.22%) on 15,454,931 shares traded after BioCryst Successfully Completed Its Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is currently up (+251.85%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Mylan, Inc. (NASDAQ:MYL) a company that engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients worldwide closed down in its previous session (-0.06%) on 2,447,794 shares traded after Mylan Announced to Host Investor Day on Aug. 1, 2013 in New York City. Mylan, Inc. (NASDAQ:MYL) is currently down (-1.63%) from its recent 52-week high which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Mylan, Inc. (NASDAQ:MYL)
GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.GrowingStockReport.com
GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.
Growing Stock Report